A study has identified seven proteins in the blood that, measured together, give a clearer picture of Alzheimer's disease than existing single-marker tests. The researchers report that a broader panel of markers does more than confirm whether the disease is present - it helps distinguish where a person sits in the disease process, which in turn should support more accurate treatment decisions.
That distinction matters because of how Alzheimer's unfolds. Amyloid plaques accumulate in the brain first, followed by thread-like tangles of the protein tau, and both damage nerve cells years before anyone notices memory problems. For most of the field's history, diagnosis leaned on cognitive changes, which surface only after considerable damage has been done. Biomarker testing existed, but it meant a lumbar puncture for cerebrospinal fluid or a PET scan, both confined to specialist centers.
Blood tests such as p-tau217 have widened access considerably, and they are good at flagging Alzheimer's pathology. Their weakness is staging: they say less about how far the disease has progressed or how quickly it is likely to advance, and they still fall short of PET imaging on that front. A multi-protein panel is an attempt to close that gap without sending patients back to the scanner.
The practical stakes are rising as treatments that target amyloid enter clinical use, since those therapies work best when the disease stage is known and matched to the drug. A blood test that can indicate stage as well as presence would make that matching feasible in ordinary clinics rather than only in research settings.